Cipla Ltd.

Cipla, a global pharmaceutical company, has received United States Food and Drug Administration (USFDA) approval for an innovative formulation - Lopinavir/ ritonavir (LPV/r) 40mg/ 10 mg oral pellets - for paediatric specific treatment for infants.

Cipla has long recognized the lack of access to life saving child-friendly formulations for the treatment of HIV, which prompted it to develop an innovative formulation of LPV/r oral pellets. The pellets are to be sprinkled on sweetened porridge for infants and administered to them. The pellets are produced by melt-extrusion technology and are enclosed in capsules.

Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 150 countries. Its portfolio includes over 1500 products across wide range of therapeutic categories with one quality standard globally.